Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Apr;6(2):113-8.
doi: 10.1215/s1152851703000462.

Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy

Affiliations
Comparative Study

Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy

Weizhen Xu et al. Neuro Oncol. 2004 Apr.

Abstract

Craniospinal radiation therapy (CSRT) combined with chemotherapy results in significant endocrine morbidity. Between 1987 and 1990, a trial using 18 Gy was conducted to treat 10 young children with medulloblastoma. There were 7 survivors. We compared the endocrine outcome in these children (group 18 Gy) to that of a comparable group treated with conventional doses of CSRT that ranged from 23 to 39 Gy (group CD). Both groups had an identical history of chemotherapy and tumor stage and were treated with recombinant growth hormone therapy (rhGH). The mean age of group 18 Gy at diagnosis was 4.0 years, and rhGH treatment was initiated in 6 children at age 9.2 years. Group CD (12 children) was diagnosed at a mean age of 5.8 years and rhGH started in 11 children at a mean age of 9.6 years. The dose of rhGH used in both groups was identical (0.3 mg/kg/wk). For group 18 Gy, adult heights and sitting heights (a mean standard deviation score of -1.01 +/- 1.11 and -1.62 +/- 1.16, respectively) were statistically greater (P < 0.05) than those for group CD (mean standard deviation score of -2.04 +/- 0.83 and -3.16 +/- 1.43, respectively). Moreover, adult heights of group 18 Gy were not different from midparental heights, unlike group CD, whose adult heights were less than midparental heights (P < 0.0001). Of other endocrine sequelae, 10 patients of the CD group were hypothyroid, 3 had adrenal insufficiency, 3 had hypogonadism, and 2 had early puberty. In contrast, within group 18 Gy, only 1 was hypothyroid (P = 0.006) and 1 had early puberty. We conclude that endocrine morbidity was significantly reduced with 18 Gy CSRT in young children with medulloblastoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Comparison of adult heights and midparental heights (SD scores). Mean adult height for group CD was −2.04 (n = 11). The mean adult height for group 18 Gy was −1.01 (n = 6). The bars represent mean height SD score. Abbreviations: Ht, height; MPHt, midparental height; NS, not significant.
Fig. 2
Fig. 2
Sitting height. Mean sitting height SD scores for group 18 Gy (n = 5) and group CD (n = 10) are compared. The bars represent mean sitting height SD score.

Similar articles

Cited by

References

    1. Adan L, Sainte-Rose C, Souberbielle JC, Zucker JM, Kalifa C, Brauner R. Adult height after growth hormone (GH) treatment for GH deficiency due to cranial irradiation. Med Pediatr Oncol. 2000;34:14–19. - PubMed
    1. Burns EC, Tanner JM, Preece MA, Cameron N. Growth hormone treatment in children with craniopharyngioma: Final growth status. Clin Endocrinol. 1981;14:587–595. - PubMed
    1. CDC/NCHS. Centers for Disease Control, National Center for Health Statistics (2002) 2000 CDC Growth Charts: United States. Available at http://www.cdc.gov/growthcharts - PubMed
    1. Clarson CL, Del Maestro RF. Growth failure after treatment of pediatric brain tumors. Pediatrics. 1999;103:E37. - PubMed
    1. Clayton PE, Shalet SM, Price DA, Addison GM. Growth and growth hormone responses to oxandrolone in boys with constitutional delay of growth and puberty (CDGP) Clin Endocrinol. 1988;29:123–130. - PubMed

Publication types

MeSH terms